The alkylate produced through a series of Lummus’ technologies, is a bio-based, low carbon intensity fuel blending component. Leon de Bruyn, chief executive officer at Lummus Technology ...

The Company expects clinical data analysis to be completed in the fourth calendar quarter of 2024 and to submit the 510(k) package during the same quarter. About Intelligent Bio Solutions Inc.

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%.

Dr. Stephen K. Aoki, Professor and Chief of Sports Medicine, specializes in the surgical treatment of pediatric, adolescent, and adult sports injuries, primarily of the hip and knee. Dr. Aoki serves ...

particularly those identified in the risk factors discussion in bluebird bio’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings with the SEC. The forward ...

Biotech tackles climate change with innovations, from carbon-neutral facilities to reducing emissions. At COP28, BIO highlighted that biotech is key to climate tech. As the global population ...